218 related articles for article (PubMed ID: 32048620)
21. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C; Charakorn C; Chittithaworn S; Lertkhachonsuk AA
J Obstet Gynaecol; 2022 Aug; 42(6):2331-2335. PubMed ID: 35470751
[TBL] [Abstract][Full Text] [Related]
23. Oral etoposide for refractory or recurrent epithelial ovarian cancer.
Thavaramara T; Tangjitgamol S; Manusirivithaya S; Leelahakorn S
J Med Assoc Thai; 2009 Nov; 92(11):1397-405. PubMed ID: 19938729
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
25. A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.
Gebbia V; Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scollo P
J Oncol Pharm Pract; 2024 Jul; 30(5):853-859. PubMed ID: 37501558
[TBL] [Abstract][Full Text] [Related]
26. Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer.
Uysal M; Ozdogan M; Kargi A; Gunduz S; Sezgin Goksu S; Murat Tatli A; Arslan D; Mutlu H; Senol Coskun H; Bozcuk H
J BUON; 2014; 19(4):980-4. PubMed ID: 25536605
[TBL] [Abstract][Full Text] [Related]
27. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
28. Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
Sharma A; Kataria B; Biswas B; Bakhshi S; Pushpam D
J Oncol Pharm Pract; 2022 Apr; 28(3):560-568. PubMed ID: 33719725
[TBL] [Abstract][Full Text] [Related]
29. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A
Ann Oncol; 2018 Mar; 29(3):737-743. PubMed ID: 29267856
[TBL] [Abstract][Full Text] [Related]
30. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Patil VM; Noronha V; Joshi A; Dhumal S; Mahimkar M; Bhattacharjee A; Gota V; Pandey M; Menon N; Mahajan A; Sable N; Kumar S; Nawale K; Mukadam S; Solanki B; Das S; Simha V; Abraham G; Chandrasekharan A; Talreja V; DSouza H; Srinivas S; Kashyap L; Banavali S; Prabhash K
J Clin Oncol; 2019 Nov; 37(32):3032-3041. PubMed ID: 31539316
[TBL] [Abstract][Full Text] [Related]
32. A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.
Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scibilia G; Scollo P; Gebbia V
J Oncol Pharm Pract; 2024 Jan; 30(1):173-181. PubMed ID: 38018146
[TBL] [Abstract][Full Text] [Related]
33. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.
Ferrandina G; Corrado G; Mascilini F; Malaguti P; Samaritani R; Distefano M; Masciullo V; Di Legge A; Savarese A; Scambia G
BMC Cancer; 2014 Dec; 14():947. PubMed ID: 25495785
[TBL] [Abstract][Full Text] [Related]
34. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
Berthold F; Hömberg M; Proleskovskaya I; Mazanek P; Belogurova M; Ernst A; Sterba J
Pediatr Hematol Oncol; 2017 Aug; 34(5):308-319. PubMed ID: 29148865
[TBL] [Abstract][Full Text] [Related]
35. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Fruehauf JP; El-Masry M; Osann K; Parmakhtiar B; Yamamoto M; Jakowatz JG
Cancer Chemother Pharmacol; 2018 Aug; 82(2):353-360. PubMed ID: 29943192
[TBL] [Abstract][Full Text] [Related]
37. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A; Chocholous M; Sabel M; Lassaletta A; Sterba J; Leblond P; Nysom K; Torsvik I; Chi SN; Perwein T; Jones N; Holm S; Nyman P; Mörse H; Öberg A; Weiler-Wichtl L; Leiss U; Haberler C; Schmook MT; Mayr L; Dieckmann K; Kool M; Gojo J; Azizi AA; André N; Kieran M; Slavc I
JAMA Oncol; 2023 Dec; 9(12):1688-1695. PubMed ID: 37883081
[TBL] [Abstract][Full Text] [Related]
38. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
El Bary NA; Hashem T; Metwally H; Ghany AA; El Mageed HA
Hematol Oncol Stem Cell Ther; 2010; 3(1):13-8. PubMed ID: 20231809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]